Prof Kanta Subbarao
Honorary (Professorial Fellow)
Department of Microbiology and Immunology
428 Scholarly works
68 Projects
HIGHLIGHTS
2026
Journal article
Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59
DOI: 10.1038/s41541-025-01355-y2026
Journal article
Influenza vaccine responses differ between young children previously exposed to influenza antigens via infection versus vaccination
DOI: 10.1038/s43856-026-01610-w2026
Journal article
ThePlatform trialInCOVID-19 priming andBOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults
DOI: 10.1016/j.vaccine.2026.1289702026
Journal article
Epistasis facilitates the long-term antigenic evolution of the influenza B virus hemagglutinin.
DOI: 10.64898/2026.07.22.7399942026
Research grants (ARC, NHMRC, MRFF)
Transforming Knowledge on Long-Term Protective Immunity by mRNA and Protein Vaccines
2024
Research grants (international)
(CRA With Melbourne Health and Aus Bio) Development of a Novel Long Acting Pan-Influenza Antiviral Drug
2021
Research grants (ARC, NHMRC, MRFF)
Chimeric Next Generation COVID Vaccines
RECENT SCHOLARLY WORKS
2026
Journal article
Delivery of monoclonal antibodies using mRNA lipid nanoparticles confers protection against SARS-CoV-2 and influenza
DOI: 10.1016/j.omtn.2026.1028732026
Journal article
Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia
DOI: 10.1016/j.jinf.2026.1067272026
Journal article
Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial
DOI: 10.1093/infdis/jiaf5682026
Journal article
Nomenclature for Tracking of Genetic Variation of Seasonal Influenza Viruses
DOI: 10.1111/irv.702302026
Journal article
Antibody responses following COVID-19 vaccination and breakthrough infections in naïve and convalescent individuals suggest imprinting to the ancestral strain of SARS-CoV-2
DOI: 10.1128/mbio.03221-252026
Journal article
SARS-CoV-2 infection patterns and immune responses by fourth-dose COVID-19 vaccination status
DOI: 10.1016/j.anzjph.2026.100489
RECENT PROJECTS
2024
Research contracts (non-grants)
Leyden SARS2/NL63 Block Contract - Assessment of the Antiviral Agents Against SARS-CoV-2 and Human Coronavirus NL63
2025
Research grants (other domestic)
Developing CRISPR Cas13 Antiviral Therapeutics for Respiratory Pathogens of Pandemic Potential